| The biomedical sector is gripped by the imminent threat, or promise, of consolidation. Many company founders and investors may lose their investments and the efforts of the last five years without a flexible response to the strains imposed on their current business plans. For some, the only alternative will be to restructure their business strategy and to adjust to the needs of the changing market conditions.In such challenging times, seeking an alternative approach to the traditional financing of biomedical businesses may be prudent. This article aims to review some of the better known choices for companies at each stage of development, and to introduce a new alternative approach which may be of vital interest in the future, particularly for those at a later stage of development. |
